These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 19047167)

  • 1. Preventive vaccination with telomerase controls tumor growth in genetically engineered and carcinogen-induced mouse models of cancer.
    Mennuni C; Ugel S; Mori F; Cipriani B; Iezzi M; Pannellini T; Lazzaro D; Ciliberto G; La Monica N; Zanovello P; Bronte V; Scarselli E
    Cancer Res; 2008 Dec; 68(23):9865-74. PubMed ID: 19047167
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate stem cell antigen vaccination induces a long-term protective immune response against prostate cancer in the absence of autoimmunity.
    Garcia-Hernandez Mde L; Gray A; Hubby B; Klinger OJ; Kast WM
    Cancer Res; 2008 Feb; 68(3):861-9. PubMed ID: 18245488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer.
    Kim S; Lee JB; Lee GK; Chang J
    Prostate; 2009 Jun; 69(9):938-48. PubMed ID: 19267351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo effects of vaccination with six-transmembrane epithelial antigen of the prostate: a candidate antigen for treating prostate cancer.
    Garcia-Hernandez Mde L; Gray A; Hubby B; Kast WM
    Cancer Res; 2007 Feb; 67(3):1344-51. PubMed ID: 17283172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccination with a DNA vaccine based on human PSCA and HSP70 adjuvant enhances the antigen-specific CD8+ T-cell response and inhibits the PSCA+ tumors growth in mice.
    Zhang X; Yu C; Zhao J; Fu L; Yi S; Liu S; Yu T; Chen W
    J Gene Med; 2007 Aug; 9(8):715-26. PubMed ID: 17595048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A TLR9 agonist enhances therapeutic effects of telomerase genetic vaccine.
    Conforti A; Cipriani B; Peruzzi D; Dharmapuri S; Kandimalla ER; Agrawal S; Mori F; Ciliberto G; La Monica N; Aurisicchio L
    Vaccine; 2010 Apr; 28(20):3522-30. PubMed ID: 20332048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo plasmid electroporation induces tumor antigen-specific CD8+ T-cell responses and delays tumor growth in a syngeneic mouse melanoma model.
    Kalat M; Küpcü Z; Schüller S; Zalusky D; Zehetner M; Paster W; Schweighoffer T
    Cancer Res; 2002 Oct; 62(19):5489-94. PubMed ID: 12359758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunization with truncated sequence of Telomerase Reverse Transcriptase induces a specific antitumor response in vivo.
    Qiu J; Li GW; Sui YF; Sun YJ; Huang YY; Si SY; Ge W
    Acta Oncol; 2007; 46(7):961-8. PubMed ID: 17917827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
    Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
    Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy of murine colon cancer using receptor tyrosine kinase EphA2-derived peptide-pulsed dendritic cell vaccines.
    Yamaguchi S; Tatsumi T; Takehara T; Sakamori R; Uemura A; Mizushima T; Ohkawa K; Storkus WJ; Hayashi N
    Cancer; 2007 Oct; 110(7):1469-77. PubMed ID: 17685394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Specific antitumor immune response induced by a novel DNA vaccine composed of multiple CTL and T helper cell epitopes of prostate cancer associated antigens.
    Qin H; Zhou C; Wang D; Ma W; Liang X; Lin C; Zhang Y; Zhang S
    Immunol Lett; 2005 Jun; 99(1):85-93. PubMed ID: 15894116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells.
    Nair SK; Heiser A; Boczkowski D; Majumdar A; Naoe M; Lebkowski JS; Vieweg J; Gilboa E
    Nat Med; 2000 Sep; 6(9):1011-7. PubMed ID: 10973321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccination with liposome--DNA complexes elicits enhanced antitumor immunity.
    U'Ren L; Kedl R; Dow S
    Cancer Gene Ther; 2006 Nov; 13(11):1033-44. PubMed ID: 16841080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Versatile prostate cancer treatment with inducible caspase and interleukin-12.
    Nikitina EY; Desai SA; Zhao X; Song W; Luo AZ; Gangula RD; Slawin KM; Spencer DM
    Cancer Res; 2005 May; 65(10):4309-19. PubMed ID: 15899823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancement of cellular immune response to a prostate cancer DNA vaccine by intradermal electroporation.
    Roos AK; Moreno S; Leder C; Pavlenko M; King A; Pisa P
    Mol Ther; 2006 Feb; 13(2):320-7. PubMed ID: 16185933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Partially circumventing peripheral tolerance for oncogene-specific prostate cancer immunotherapy.
    Neeley YC; Arredouani MS; Hollenbeck B; Eng MH; Rubin MA; Sanda MG
    Prostate; 2008 May; 68(7):715-27. PubMed ID: 18302222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccination strategy determines the emergence and dominance of CD8+ T-cell epitopes in a FVB/N rat HER-2/neu mouse model of breast cancer.
    Singh R; Paterson Y
    Cancer Res; 2006 Aug; 66(15):7748-57. PubMed ID: 16885378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Truncated TERT mRNA transfected dendritic cells evoke TERT specific antitumor response in vivo.
    Qiu J; Lil GW; Sui YF; Sun YJ; Huang YY; Si SY; Ge W; Song HP
    Hepatogastroenterology; 2007; 54(75):681-7. PubMed ID: 17591041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A modified epitope identified for generation and monitoring of PSA-specific T cells in patients on early phases of PSA-based immunotherapeutic protocols.
    Lundberg K; Roos AK; Pavlenko M; Leder C; Wehrum D; Guevara-Patiño J; Andersen RS; Pisa P
    Vaccine; 2009 Mar; 27(10):1557-65. PubMed ID: 19171173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concomitant tumor and minor histocompatibility antigen-specific immunity initiate rejection and maintain remission from established spontaneous solid tumors.
    Hess Michelini R; Freschi M; Manzo T; Jachetti E; Degl'Innocenti E; Grioni M; Basso V; Bonini C; Simpson E; Mondino A; Bellone M
    Cancer Res; 2010 May; 70(9):3505-14. PubMed ID: 20388780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.